Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America
INMB
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America
INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America
IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America
INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America
TIL
Intellia Therapeutics, Inc. Logo
Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.
United States of America
NTLA
Intercure Ltd. Logo
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel
INCR
Intervacc AB Logo
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden
IVACC
iNtRON Biotechnology, Inc. Logo
Develops phage therapeutics and molecular diagnostics to combat infectious diseases.
South Korea
048530

Talk to a Data Expert

Have a question? We'll get back to you promptly.